Tag: Dr David Dworaczyk
Bryn Pharma Raises Another $15 Million for Commercialization of Needle-Free Intranasal...
Company is developing UTULY for intranasal emergency epinephrine delivery.
Bryn Shows UTULY™ Intranasal Epinephrine Absorbs Faster and is Sustained Longer...
A needleless, self administered nasal spray intended to be used in anaphylactic emergencies in place of traditional auto-injectors.
Bryn Pharma Completes Study of Nasal Epinephrine vs Auto-Injector for Anaphylaxis
Nasal administration of epinephrine takes another step forward.
Bryn Study Evaluates Effects of Nasal Congestion on Intranasal Administration of...
“A treatment method like intranasal delivery that is easier and more convenient may lead to increased compliance and result in a reduced time to treat an anaphylactic event.”
Bryn Pharma Research on Epinephrine Nasal Spray Presented at ACAAI Annual...
Two studies shed light on the viability of intranasal delivery of emergency epinephrine.
Bryn Pharma Partners with Aptar Pharma for Nasal Epinephrine Treatment
Bryn’s epinephrine nasal spray provides two doses in one portable device.
Bryn Pharma Completes Dosing in Pivotal Clinical Trial Designed to Support...
Nasal Spray Product is Disruptive Innovation for People at Risk of Anaphylaxis.
